More JUNK LYME SCIENCE from Shapiro that should be retracted. Waiting on a reply.

Photo of Shapiro was found on his Yale.edu profile page:
https://medicine.yale.edu/profile/eugene-shapiro/

---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "eugene.shapiro@yale.edu" <eugene.shapiro@yale.edu>, "marietta.vazques@yale.edu" <marietta.vazques@yale.edu>
Cc: "roger.bedimo@utsouthwestern.edu" <roger.bedimo@utsouthwestern.edu>, "James.Cutrell@utsouthwestern.edu" <James.Cutrell@utsouthwestern.edu>, "john.carlisle@nhs.net" <john.carlisle@nhs.net>, "marcia_angell@hms.harvard.edu" <marcia_angell@hms.harvard.edu>
Date: 09/27/2023 11:13 AM EDT
Subject: Clinical Effectiveness of Lyme Vaccine: A Matched Case–Control Study 
 
 
Open Forum Infectious Diseases
Published: 17 April 2021
 
Clinical Effectiveness of Lyme Vaccine: A Matched Case–Control Study 
Carlos R Oliveira, Christopher Massad, Eugene D Shapiro, Marietta Vazquez
https://academic.oup.com/ofid/article/8/8/ofab142/6232196
 
 
 
Eugene Shapiro, MD, Corresponding Author
Professor of Pediatrics, of Epidemiology and of Investigative Medicine
Yale School of Medicine
 
 
Dear Dr. Shapiro,
 
As a member of New Hampshire Governor Chris Sununu’s 2020-2021 commission to study diagnostic testing for Lyme disease, I read your manuscript with great interest. After a full year of deliberation, study results concluded that the FDA approved two-tier serologic test for Lyme was not reliable in all stages of disease. (No better than a coin toss)
 
COMMISSION TO STUDY TESTING FOR LYME AND OTHER TICK-BORNE DISEASES
https://www.gencourt.state.nh.us/statstudcomm/committees/default.aspx?id=1515
 
“A commission to study the role of clinical diagnosis and the limitations of serological diagnostic tests in determining the presence or absence of Lyme and other tick-borne diseases”
 
With that conclusion, serology cannot be used to determine who has or does not have Lyme disease. Excluding patients in your “case-control study” who did not meet the CDC’s criteria for positive test results is disingenuous.
 
 
Excerpt from your article:
 
“Cases were excluded if, after review of their medical records, they did not meet the National Notifiable Disease Surveillance System’s case definition for Lyme disease: physician diagnosed erythema migrans measuring  5cm, or a positive two-tier serologic test (interpreted using established CDC criteria) and objective evidence of an extracutaneous manifestation of Lyme disease (e.g., facial nerve palsy, meningitis, radiculopathy, carditis, or arthritis) [8].”
 
 
The CDC has warned the medical community that “surveillance case definitions” are not to be used for making a clinical diagnosis:
 
From the CDC website:
 
Lyme Disease (Borrelia burgdorferi) 
2022 Case Definition
https://ndc.services.cdc.gov/case-definitions/lyme-disease-2022/
 
NOTE: A surveillance case definition is a set of uniform criteria used to define a disease for public health surveillance. Surveillance case definitions enable public health officials to classify and count cases consistently across reporting jurisdictions. Surveillance case definitions are not intended to be used by healthcare providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.
 
 
Lyme Disease Nonprofit Calls for Suspension of Pfizer Lyme Vaccine Trial
https://www.trialsitenews.com/a/lyme-disease-nonprofit-calls-for-suspension-of-pfizer-lyme-vaccine-trial-c3154a04
 
"There is no accurate diagnostic test to determine if subjects in the placebo arm get Lyme disease at a higher rate than subjects in the vaccinated study arm," putting volunteers at significant risk of contracting the disease without an ability to diagnose it.
 
Continued...
 
 
Dr. Shapiro... Your conclusion that LymeRix was “71% effective” at preventing Lyme disease is 100% misleading to the public and medical community and your paper should be considered for retraction.
 
A copy of this email has been sent to Roger J. Bedimo, MD Editor-in-Chief.
 
 
Respectfully submitted,
 
 
Carl Tuttle
Hudson, NH
 
 
Cc: Roger J. Bedimo, MD Editor-in-Chief
 
John Carlisle, Consultant Intensive Care, Perioperative Medicine and Anaesthesia
 
Staggering Levels of Potential Misrepresentation & Fraud Associated with Medical Journal Entries
https://www.trialsitenews.com/a/staggering-levels-of-potential-misrepresentation-fraud-associated-with-medical-journal-entries-baf9e0ab
 
 
NEJM editor: “No longer possible to believe much of clinical research published”
https://www.diversehealthservices.com/blog/NEJM-editor-No-longer-possible-to-believe-much-of-clinical-research-published_AE4.html?view=5GR22
 
“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.” -Dr. Marcia Angell